INDEX

VOLUME 25 1970

A

AOAC: Why FDA Analyses Stick. Nov., p. 487.

Aarons, Morris—Drug Dating. Apr., p. 185.

Additives, Standards, and Nutritional Contributions of Foods. Feb., p. 83.

Adelman, Benjamin—AOAC: Why FDA Analyses Stick. Nov., p. 487.

Administration and Enforcement

IDIP and Citation Hearings—Rights, Responsibilities and Opportunities. Sept., p. 404.

New FTC Approaches to Food, Drug and Cosmetic Problems. Apr., p. 172.

Problems in the Administration and Enforcement of Food Laws. Sept., p. 429.

Reasonable Grounds, Substantial Evidence, and Law and Order. Apr., p. 210.

Right to a Hearing in New Drug Revocation and Antibiotic Decertification Proceedings (The). Nov., p. 476.

State Agencies Protect Consumers. Dec., p. 513.

Trial of an Injunction Suit (The). May, p. 238.

Analysis and Recommendations — The Food and Drug Organizational Review. Jan., p. 22.

Analysis and Testing

AOAC: Why FDA Analyses Stick. Nov., p. 487.

Evaluation of the Salmonella Problem (An). Feb., p. 60.

Food Safety. Nov., p. 495.

National Center for Drug Analysis (The). Mar., p. 135.

National Center for Microbiological Analysis. Feb., p. 65.

Preclinical Investigations. Dec., p. 539.

Toxic Substances Naturally Present in Food. Aug., p. 387.

Angevine, Erma—The Right to Excellence. Jan., p. 43.

Augustinsson, Bengt — Sweden's New Food Law. Aug., p. 382.

B

Banes, Daniel—The National Center for Drug Analysis. Mar., p. 135.

Barnard, Alfred—Food GMPs. Mar., p. 123.

Berch, Irwin B. — FDA's Intensified Drug Inspection Program. Feb., p. 101.

Burditt, George M.

Consumer Protection Aspects of the Federal Food, Drug, and Cosmetic Act. June, p. 268.

The Trial of an Injunction Suit. May, p. 238.

Buyer's Rights. Jan., p. 48.

C

Campbell, J. A.—Mechanisms for Setting Food Standards in Canada. Mar., p. 140.

Chapman, Ross A.—Recent Changes in Canadian Food and Drug Legislation. July, p. 338.

Codex Alimentarius Commission

Report of the Seventh Session of the Joint FAO/WHO Codex Alimentarius Commission. June, p. 284.

XVI Conference of the Inter-American Bar Association. June, p. 307.

Cody, William F.

GMP Regulations. Mar., p. 116.

New Foods and the Imitation Provisions of the Food, Drug, and Cosmetic Act. May, p. 220.

Condon, William J.

Plaintiff's Fault as a Defense to Strict Liability. May, p. 246.

XUM

Product Liability—1969. Mar., p. 158.
Consumer-Business Partnership (The). Dec., p. 519.
Consumer Expectations from the White House Nutrition Conference. Dec., p. 531.
Consumer Protection
Buyer's Rights. Jan., p. 48.
Consumer - Business Partnership (The). Dec., p. 519.
Consumer Expectations from the White House Nutrition Conference. Dec., p. 531.
Consumer Protection Aspects of the Federal Food, Drug, and Cosmetic Act. June, p. 268.
Consumerism's Ultimate Challenge: Is Business Equal to the Task? Jan., p. 17.
Food Safety. Nov., p. 495.
National Better Business Bureau (The). Jan., p. 52.
Progress in Consumer Protection. Jan., p. 29.
Right to Excellence (The). Jan., p. 43.
Trends in Product Safety Protection. Oct., p. 460.
White House Recommendations: FDA's Goals and Progress. Dec., p. 525.
Consumer Protection Aspects of the Federal Food, Drug, and Cosmetic Act. June, p. 268.
Consumerism's Ultimate Challenge: Is Business Equal to the Task? Jan., p. 17.
Current GMP Regulations Applicable to the Human Food Industry. June, p. 279.

D

D'Aguanno, William—Preclinical Investigations. Dec., p. 539.
D'Andrade, Hugh A.—The Effect of NAS/NRC Review on Me-Too and Post-'62 Drugs. July, p. 330.
Depew, Franklin M.
Introductory Statement. Mar., p. 147.
Report of the Seventh Session of the Joint FAO/WHO Codex Alimentarius Commission. June, p. 284.
Drug Consultation
Legal Considerations for the Pharmacist Undertaking New Drug Consultation Responsibilities. Oct., p. 444.
Drug Dating. Apr., p. 185.

E

Edwards, Charles C.—FDA—Today and Tomorrow. Dec., p. 508.
Effect of NAS/NRC Review on Me-Too and Post-'62 Drugs (The). July, p. 330.
Effectiveness of the NAS-NRC Drug Effectiveness Review. Feb., p. 91.
Elkas, Robert W.—Revised Good Manufacturing Practice Regulations. Feb., p. 78.
Evaluation of the Salmonella Problem (An). Feb., p. 60.

F

FDA Procedures. Apr., p. 191.
FDA—Today and Tomorrow. Dec., p. 508.
FDA's Intensified Drug Inspection Program. (Irwin B. Berch) Feb., p. 101.
FDA's Intensified Drug Inspection Program. (H. A. Frediani) Mar., p. 131.
Fair Packaging and Labeling
Consumer Expectations from the White House Nutrition Conference. Dec., p. 531.
Fourth Dimension in Labeling: Trademark Consequences of an Improper Label (The).—Part I. July, p. 347.
Fourth Dimension in Labeling: Trademark Consequences of an Improper Label (The)—Part II. Aug., p. 372.
Some Present Responsibilities in Labeling and Advertising (Part II). Jan., p. 4.
White House Recommendations: FDA's Goals and Progress. Dec., p. 525.
Fault in Marketing—As an Element of a Manufacturers' Strict Liability. May, p. 254.
Field, Thomas G., Jr.
The Fourth Dimension in Labeling: Trademark Consequences of an Improper Label—Part I. July, p. 347.

The Fourth Dimension in Labeling: Trademark Consequences of an Improper Label—Part II. Aug., p. 372.

Food Additives

Additives, Standards, and Nutritional Contributions of Foods. Feb., p. 83.

Food Safety. Nov., p. 495.

Other Considerations in Foods and Food Additives. Feb., p. 70.

Food and Drug Administration

Analysis and Recommendations—The Food and Drug Organizational Review. Jan., p. 22.

FDA Procedures. Apr., p. 191.

FDA Today and Tomorrow. Dec., p. 508.

FDA's Intensified Drug Inspection Program. (Irwin B. Berch) Feb., p. 101.

FDA's Intensified Drug Inspection Program. (H. A. Frediani) Mar., p. 131.

Freedom of Information Act and the FDA (The). June, p. 296.

Food, Drug, and Cosmetic Act

Consumer Protection Aspects of the Federal Food, Drug, and Cosmetic Act. June, p. 268.

New Foods and the Imitation Provisions of the Food, Drug, and Cosmetic Act. May, p. 220.

Real Food and Drug Law (The). July, p. 316.

Food GMPs. Mar., p. 123.

Food Laws and Their Influence on International Trade. Oct., p. 453.

Food Safety. Nov., p. 495.

Food Standards. Feb., p. 74.

Food Standards

Additives, Standards, and Nutritional Contributions of Foods. Feb., p. 83.

Consumer - Business Partnership. (The). Dec., p. 519.

Food Laws and Their Influence on International Trade. Oct., p. 453.

Food Safety. Nov., p. 495.

Food Standards. Feb., p. 74.

Mechanisms for Setting Food Standards in Canada. Mar., p. 140.

New Foods and the Imitation Provisions of the Food, Drug, and Cosmetic Act. May, p. 220.

Nutritional Considerations in Foods. Jan., p. 38.

Recent Changes in Canadian Food and Drug Legislation. July, p. 338.

XVI Conference of the Inter-American Bar Association. June, p. 307.

Sweden's New Food Law. Aug., p. 382.

White House Recommendations: FDA's Goals and Progress. Dec., p. 525.

Forman, Howard I.—How the Chemical-Pharmaceutical Industry Views the Government's Patent Policy. Apr., p. 204.

Foster, E. M.—An Evaluation of the Salmonella Problem. Feb., p. 60.

Fourth Dimension in Labeling: Trademark Consequences of an Improper Label (The)—Part I. July, p. 347.

Fourth Dimension in Labeling: Trademark Consequences of an Improper Label (The)—Part II. Aug., p. 372.

Frediani, H. A.—FDA's Intensified Drug Inspection Program. Mar., p. 131.

Freedom of Information Act and the FDA (The). June, p. 296.

Freedom of Information Act

Freedom of Information Act and the FDA (The). June, p. 296.

Function of Guaranties (The). Mar., p. 150.

G

GMP Regulations. Mar., p. 116.

Geary, Nathaniel L.—Self-Certification of Foods: A Progress Report. Mar., p. 127.

Gilbert, Gerald E.—The Legal Status of Devices. Apr., p. 179.

Good Manufacturing Practice Regulations

Current GMP Regulations Applicable to the Human Food Industry. June, p. 279.

Food GMPs. Mar., p. 123.

GMP Regulations. Mar., p. 116.

Revised Good Manufacturing Practice Regulations. (Robert W. Elkas) Feb., p. 78.

Revised Good Manufacturing Practice Regulations. (Robert W. Jennings) Feb., p. 107.

XUM

H

Hall, Richard L.—Toxic Substances Naturally Present in Food. Aug., p. 387.

Harmonization of Food Laws

Food Laws and Their Influence on International Trade. Oct., p. 453.

Recent Changes in Canadian Food and Drug Legislation. July, p. 338.

Report of the Seventh Session of the Joint FAO/WHO Codex Alimentarius Commission. June, p. 284.

XVI Conference of the Inter-American Bar Association. June, p. 307.

Sweden's New Food Law. Aug., p. 382.

Hart, Sam—Trends in Product Safety Protection. Oct., p. 460.

Hazleton, L. W.—Other Considerations in Foods and Food Additives. Feb., p. 70.

How the Chemical-Pharmaceutical Industry Views the Government's Patent Policy. Apr., p. 204.

I

IDIP and Citation Hearings—Rights, Responsibilities and Opportunities. Sept., p. 404.

Imitation and Artificial Foods

New Foods and the Imitation Provisions of the Food, Drug, and Cosmetic Act. May, p. 220.

Nutritional Considerations in Foods. Jan., p. 38.

Toxic Substances Naturally Present in Food. Aug., p. 387.

Intensified Drug Inspection Program. Apr., p. 197.

Intensified Drug Inspection Program

FDA's Intensified Drug Inspection Program. (Irwin B. Berch) Feb., p. 101.

FDA's Intensified Drug Inspection Program. (H. A. Frediani) Mar., p. 131.

IDIP and Citation Hearings—Rights, Responsibilities and Opportunities. Sept., p. 404.

Intensified Drug Inspection Program. Apr., p. 197.

Introductory Statement. Mar., p. 147.

J

Jennings, Robert W.—Revised Good Manufacturing Practice Regulations. Feb., p. 107.

Johnstone, James M.—The Freedom of Information Act and the FDA. June, p. 296.

K

Karl, Paul M.—Food Laws and Their Influence on International Trade. Oct., p. 453.

Kleinfeld, Vincent A.—Reasonable Grounds, Substantial Evidence, and Law and Order. Apr., p. 210.

Klinger, Tobias G.—IDIP and Citation Hearings—Rights, Responsibilities and Opportunities, Sept., p. 404.

Knauer, Virginia H.—Buyer's Rights. Jan., p. 48.

L

Legal Considerations for the Pharmacist Undertaking New Drug Consultation Responsibilities. Oct., p. 444.

Legal Status of Devices (The). Apr., p. 179.

Legislation

Drug Dating. Apr., p. 185.

Function of Guaranties (The). Mar., p. 150.

How the Chemical-Pharmaceutical Industry Views the Government's Patent Policy. Apr., p. 204.

Introductory Statement. Mar., p. 147.

Legal Status of Devices (The). Apr., p. 179.

New Foods and the Imitation Provisions of the Food, Drug, and Cosmetic Act. May, p. 220.

Recent Changes in Canadian Food and Drug Legislation. July, p. 338.

Remarks on Medical Devices. Oct., p. 466.

Right to a Hearing in New Drug Revocation and Antibiotic Decertification Proceedings. Nov., p. 476.

Lewis, Keith H.—Food Standards. Feb., p. 74.

Ley, Herbert L., Jr.—Progress in Consumer Protection. Jan., p. 29.

Lindsay, Dale R.
Food Safety. Nov., p. 495.
Nutritional Considerations in Foods. Jan., p. 38.

M

Malek, Frederic V.—Analysis and Recommendations—The Food and Drug Organizational Review. Jan., p. 22.

Markel, Michael F.—Problems in the Administration and Enforcement of Food Laws. Sept., p. 429.

Maxwell, Richard—The National Better Business Bureau. Jan., p. 52.

McClellan, John G.—State Agencies Protect Consumers. Dec., p. 513.

McEwen, Robert J.—Consumer Expectations from the White House Nutrition Conference. Dec., p. 531.

McLaughlin, Frank E.—The Consumer-Business Partnership. Dec., p. 519.

Mechanisms for Setting Food Standards in Canada. Mar., p. 140.

Medical Devices
Remarks on Medical Devices. Oct., p. 466.

Metzger, Donald L.—The Real Food and Drug Law. July, p. 316.

Munsey, Rodney R.—The Right to a Hearing in New Drug Revocation and Antibiotic Decertification Proceedings. Nov., p. 476.

N

NAS-NRC Review
Effectiveness of the NAS-NRC Drug Effectiveness Review. Feb., p. 91.
Effect of NAS/NRC Review on Me-Too and Post-'62 Drugs (The). July, p. 330.
FDA Procedures. Apr., p. 191.

National Better Business Bureau (The). Jan., p. 52.

National Center for Drug Analysis (The). Mar., p. 135.

National Center for Microbiological Analysis. Feb., p. 65.

New Citadel (The): Enterprise Liability for Inherently Dangerous Products. Sept., p. 414.

New FTC Approaches to Food, Drug and Cosmetic Problems. Apr., p. 172.

New Foods and the Imitation Provisions of the Food, Drug, and Cosmetic Act. May, p. 220.

Nutritional Considerations in Foods. Jan., p. 38.

O

Olson, Joseph C., Jr.—National Center for Microbiological Analysis. Feb., p. 65.

Other Considerations in Foods and Food Additives. Feb., p. 70.

P

Patents and Trademarks
Fourth Dimension in Labeling: Trademark Consequences of an Improper Label (The)—Part I. July, p. 347.
Fourth Dimension in Labeling: Trademark Consequences of an Improper Label (The)—Part II. Aug., p. 372.
How the Chemical-Pharmaceutical Industry Views the Government's Patent Policy. Apr., p. 204.

Pendergast, William R.—FDA Procedures. Apr., p. 191.

Pharmacists' New Responsibilities
Legal Considerations for the Pharmacist Undertaking New Drug Consultation Responsibilities. Oct., p. 444.

Philpot, André L.—The New Citadel: Enterprise Liability for Inherently Dangerous Products. Sept., p. 414.

Pilot, Larry R.—Remarks on Medical Devices. Oct., p. 466.

Plaintiff's Fault as a Defense to Strict Liability. May, p. 246.

Preclinical Investigations. Dec., p. 539.

Problems in the Administration and Enforcement of Food Laws. Sept., p. 429.

Product Liability—1969. Mar., p. 158.

Product Liability
Fault in Marketing—As an Element of a Manufacturer's Strict Liability. May, p. 254.
New Citadel (The): Enterprise Liability for Inherently Dangerous Products. Sept., p. 414.

XUM

Plaintiff's Fault as a Defense to Strict Liability. May, p. 246.
Product Liability—1969. Mar., p. 158.
Trends in Product Safety Protection. Oct., p. 460.
Progress in Consumer Protection. Jan., p. 29.

R

Real Food and Drug Law (The). July, p. 316.
Reasonable Grounds, Substantial Evidence, and Law and Order. Apr., p. 210.
Recent Changes in Canadian Food and Drug Legislation. July, p. 338.
Remarks on Medical Devices. Oct., p. 466.
Report of the Seventh Session of the Joint FAO/WHO Codex Alimentarius Commission. June, p. 284.
Revised Good Manufacturing Practice Regulations. (Robert W. Elkas) Feb., p. 78.
Revised Good Manufacturing Practice Regulations. (Robert W. Jennings) Feb., p. 107.
Right to Excellence (The). Jan., p. 43.
Right to a Hearing in New Drug Revocation and Antibiotic Decertification Proceedings (The). Nov., p. 476.

S

Salmonella
Evaluation of the Salmonella Problem (An). Feb., p. 60.
Seidman, Albert G.—New FTC Approaches to Food, Drug and Cosmetic Problems. Apr., p. 172.
Self-Certification of Foods: A Progress Report. Mar., p. 127.
Self-Certification
Self-Certification of Foods: A Progress Report. Mar., p. 127.
Self-Regulation
Consumerism's Ultimate Challenge: Is Business Equal to the Task? Jan., p. 17.
National Better Business Bureau (The). Jan., p. 52.
Nutritional Considerations in Foods. Jan., p. 38.
Right to Excellence (The). Jan., p. 43.
XVI Conference of the Inter-American Bar Association. June, p. 307.
Some Present Responsibilities in Labeling and Advertising (Part II). Jan., p. 4.
Somers, Ira I.—Additives, Standards, and Nutritional Contributions of Foods. Feb., p. 83.
State Agencies Protect Consumers. Dec., p. 513.
Sweden's New Food Law. Aug., p. 382.

T

Thompson, Merrill S.
Current GMP Regulations Applicable to the Human Food Industry. June, p. 279.
The Function of Guaranties. Mar., p. 150.
Toxic Substances Naturally Present in Food. Aug., p. 387.
Trends in Product Safety Protection. Oct., p. 460.
Trial of an Injunction Suit (The). May, p. 238.

W

White House Recommendations: FDA's Goals and Progress. Dec., p. 525.
Whyte, Warren E.
Effectiveness of the NAS-NRC Drug Effectiveness Review. Feb., p. 91.
Intensified Drug Inspection Program. Apr., p. 197.
Willig, Sidney H.
Legal Considerations for the Pharmacist Undertaking New Drug Consultation Responsibilities. Oct., p. 444.
Some Present Responsibilities in Labeling and Advertising (Part II). Jan., p. 4.
Wodicka, Virgil O.—White House Recommendations: FDA's Goals and Progress. Dec., p. 525.
Woods, William P.—Fault in Marketing—As an Element of a Manufacturer's Strict Liability. May, p. 254.

Y

Yohalem, Aaron S.—Consumerism's Ultimate Challenge: Is Business Equal to the Task? Jan., p. 17.

XUM